A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid
peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will
be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is
designed to evaluate the toxicity, immunologic effects and potential therapeutic role of
repeated doses of gp100 peptide vaccines administered subcutaneously.
Immune reactivity to the gp100 epitope peptides will be monitored in all patients by
analysis of melanoma-specific T cell precursor frequency prior to and after immunization.
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
|National Cancer Institute (NCI)||Bethesda, Maryland 20892|